Intellia Therapeutics presents new lonvo‑z data and FDA BLA acceptance with priority review
Intellia Therapeutics reported additional clinical data for its hereditary angioedema therapy lonvo‑z, showing an 81% reduction in monthly attack rates in the Phase 3 HAELO trial and that all patients on a 50 mg dose were free from long‑term prophylaxis. The FDA accepted the biologics license application in September 2026, granted priority review and set a PDUFA target action date of March 10 2027. The company hosted an investor webcast to discuss the results and its commercial preparation.
Why it matters
The priority‑review status and March 10 2027 target date create a near‑term regulatory catalyst that could drive the stock if approval is granted. The efficacy data may also support pricing and market uptake assumptions for a commercial launch.
Key facts
- 1Monthly attack rates fell by 81% in patients previously on long‑term prophylaxis who received lonvo‑z in the Phase 3 HAELO trial. tradingview.com
- 2In the Phase 3 HAELO trial, 35 patients on long‑term prophylaxis were randomized to lonvo‑z, and 63% achieved complete control during the efficacy observation period. investing.com
- 3All patients receiving a 50 mg dose of lonvo‑z were free from long‑term prophylaxis in both Phase 1/2 and Phase 3 studies. tradingview.com
- 4In the Phase 1/2 study, 100% of patients on the 50 mg dose were LTP‑free at the data cutoff. investing.com
- 5Among 23 Phase 1/2 patients interviewed, 22 (96%) described lonvo‑z as an optimal therapy. tradingview.com
- 6The FDA accepted the biologics license application for lonvo‑z in September 2026, granted priority review and set a PDUFA target action date of March 10 2027. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.